Go to:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Start > Publications > View > New cardiovascular biomarkers: Clinical implications in patients with valvular heart disease
Publication

Publications

New cardiovascular biomarkers: Clinical implications in patients with valvular heart disease

Title
New cardiovascular biomarkers: Clinical implications in patients with valvular heart disease
Type
Another Publication in an International Scientific Journal
Year
2008
Authors
Moura LM
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page View ORCID page
Rocha Goncalves, F
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Zamorano, JL
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Barros, I
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Bettencourt P
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page Without ORCID
Rajamannan, N
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Journal
Vol. 6 No. 7
Pages: 945-954
ISSN: 1477-9072
Publisher: Taylor & Francis
Indexing
Other information
Authenticus ID: P-007-NG1
Abstract (EN): Valvular heart disease (VHD) is characterized by an ongoing, inflammatory cellular response which results in a left ventricular hemodynamic stress change in response to valvulopathy. The current inflammatory hypothesis suggests that as the heart valve disease progresses the inflammatory cytokine response is activated causing continuation of deleterious effects on the heart and vasculature. This can lead to progression of heart failure and left ventricular dysfunction. Over the last 10 years, a number of biologically active molecules, termed biomarkers, have been discovered in VHD. These can be used to detect the progression and pathogenesis of heart failure and to assess the severity of inflammation (e.g., C-reactive protein). Brain natriuretic peptide (BNP) can diagnose underlying cardiac systolic and diastolic dysfunction. In high-risk patients BNP is also considered to be a useful tool for assisting in the diagnosis and monitoring the progression of VHD. Patients with symptomatic VHD benefit from aortic valve surgery; however, management in the absence of symptoms remains challenging. While the lack of symptoms can delay aortic valve replacement, unselected premature aortic valve replacement may be associated with unbalanced risks of cardiac surgery. This review summarizes the current and emerging clinical and potential research application of specific biomarkers of VHD. © 2008 Expert Reviews Ltd.
Language: English
Type (Professor's evaluation): Scientific
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same journal

What role could clinical staging standardization play in Fabry disease? (2025)
Another Publication in an International Scientific Journal
Martins, E; Santos, J; Fortuna, I
New cardiovascular biomarkers: clinical implications in patients with valvular heart disease (2008)
Article in International Scientific Journal
Moura LM; Rocha-Gonçalves F
Bench to bedside defining calcific aortic valve disease: osteocardiology (2020)
Article in International Scientific Journal
Rajamannan, NM; Moura LM; Best, P
Recommend this page Top
Copyright 1996-2025 © Faculdade de Direito da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-08-31 at 18:54:01 | Privacy Policy | Personal Data Protection Policy | Whistleblowing